Investors Purchase High Volume of Put Options on Aimmune Therapeutics (AIMT)

Aimmune Therapeutics Inc (NASDAQ:AIMT) was the target of some unusual options trading activity on Thursday. Stock investors bought 1,044 put options on the company. This represents an increase of 876% compared to the average volume of 107 put options.

NASDAQ:AIMT opened at $23.34 on Friday. The company has a market cap of $1.45 billion, a PE ratio of -6.36 and a beta of -0.11. Aimmune Therapeutics has a fifty-two week low of $21.22 and a fifty-two week high of $36.12.

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in Aimmune Therapeutics by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 472,225 shares of the biotechnology company’s stock worth $11,295,000 after acquiring an additional 28,694 shares during the period. Norges Bank purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $6,035,000. Legal & General Group Plc lifted its position in Aimmune Therapeutics by 29.1% during the fourth quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 4,123 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $139,000. Finally, Opaleye Management Inc. purchased a new position in Aimmune Therapeutics during the fourth quarter valued at $3,588,000. 77.75% of the stock is owned by institutional investors.

A number of brokerages have commented on AIMT. Wedbush reiterated a “buy” rating and set a $80.00 price target on shares of Aimmune Therapeutics in a research report on Thursday, March 7th. Cantor Fitzgerald set a $45.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, February 28th. BidaskClub upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. ValuEngine cut shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $47.25.

ILLEGAL ACTIVITY NOTICE: This story was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2019/03/15/investors-purchase-high-volume-of-put-options-on-aimmune-therapeutics-aimt.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Special Dividends

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit